| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00018-011-0878-0 |
| P698 | PubMed publication ID | 22076652 |
| P2093 | author name string | Gang Li | |
| Almass-Houd Aguissa-Touré | |||
| P2860 | cites work | The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 |
| The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation | Q24290417 | ||
| Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 | ||
| TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta | Q24310394 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 | ||
| Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 | ||
| Protean PTEN: form and function | Q24613810 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 | ||
| Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
| Crystal structure of the dual specificity protein phosphatase VHR | Q27732778 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| PTEN: one gene, many syndromes | Q28203387 | ||
| Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland | Q28217001 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines | Q28256046 | ||
| Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias | Q28274383 | ||
| Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants | Q28287782 | ||
| Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma | Q28294331 | ||
| PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas | Q82600359 | ||
| Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene | Q84016729 | ||
| Methylation of PTEN as a prognostic factor in malignant melanoma of the skin | Q84616428 | ||
| PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma | Q94325481 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase | Q28567492 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | Q28590839 | ||
| A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling | Q28609913 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. | Q30487052 | ||
| PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 | ||
| Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice | Q33667276 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| Mutations of the human PTEN gene | Q33988995 | ||
| Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice | Q34009762 | ||
| Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. | Q34049618 | ||
| Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis | Q34338564 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| From form to function: signaling by protein tyrosine phosphatases. | Q34405391 | ||
| Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice | Q34479331 | ||
| Metastatic melanoma | Q34678227 | ||
| Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. | Q34742581 | ||
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 | ||
| PTEN hamartoma tumor syndrome: an overview | Q34996547 | ||
| Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
| PTEN signaling pathways in melanoma | Q35146572 | ||
| Cooperative effects of INK4a and ras in melanoma susceptibility in vivo | Q35195311 | ||
| Identification of PTEN mutations in metastatic melanoma specimens | Q35435625 | ||
| Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma | Q35577168 | ||
| JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis | Q35635353 | ||
| Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF | Q35700459 | ||
| Epigenetic PTEN silencing in malignant melanomas without PTEN mutation | Q35745799 | ||
| In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma | Q36260162 | ||
| Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. | Q36609858 | ||
| Toward a molecular classification of melanoma. | Q36795253 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| New insights into PTEN. | Q37011116 | ||
| Integrating BRAF/MEK inhibitors into combination therapy for melanoma. | Q37135238 | ||
| PTEN and the PI3-kinase pathway in cancer | Q37259680 | ||
| Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. | Q37270416 | ||
| Post-translational regulation of PTEN. | Q37270440 | ||
| The role of PTEN signaling perturbations in cancer and in targeted therapy | Q37270446 | ||
| PTEN signaling pathways in glioblastoma | Q37287036 | ||
| Faithfull modeling of PTEN loss driven diseases in the mouse | Q37765216 | ||
| APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity | Q37799221 | ||
| Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions | Q38433940 | ||
| Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study | Q39693657 | ||
| MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). | Q39728869 | ||
| Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. | Q39774233 | ||
| Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma | Q39812581 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration | Q40002542 | ||
| Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. | Q40177784 | ||
| Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. | Q40298565 | ||
| Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 | ||
| Regulation of Raf-Akt Cross-talk | Q40727585 | ||
| Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation | Q40732720 | ||
| Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity | Q40768754 | ||
| Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells | Q40782343 | ||
| Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. | Q40887108 | ||
| The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells | Q40993616 | ||
| Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme | Q41075821 | ||
| Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. | Q41377207 | ||
| Molecular genetics of familial cutaneous melanoma | Q41704108 | ||
| Pten, a protean tumor suppressor | Q42125233 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 | ||
| Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. | Q42815905 | ||
| Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines | Q42818580 | ||
| PTEN: sometimes taking it off can be better than putting it on. | Q43104730 | ||
| High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma | Q43509621 | ||
| Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. | Q43860454 | ||
| Promoter methylation and silencing of PTEN in gastric carcinoma | Q43918868 | ||
| Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer | Q43966008 | ||
| Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions | Q44467149 | ||
| Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation | Q45345194 | ||
| Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. | Q45908947 | ||
| Loss of heterozygosity for 10q22-10qter in malignant melanoma progression | Q46160835 | ||
| Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation | Q46244569 | ||
| Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma | Q46912733 | ||
| BRAF alterations are associated with complex mutational profiles in malignant melanoma | Q47349130 | ||
| The PTEN tumour suppressor gene and malignant melanoma. | Q48379706 | ||
| Somatic mutations of PTEN in glioblastoma multiforme | Q48618632 | ||
| PTEN promoter methylation in sporadic thyroid carcinomas | Q48645805 | ||
| Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis | Q49074092 | ||
| Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor | Q49086388 | ||
| PTEN mutation spectrum in breast cancers and breast hyperplasia. | Q53300858 | ||
| PTEN/MMAC1 mutations in endometrial cancers. | Q53439663 | ||
| Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. | Q53439669 | ||
| Analysis of PTEN gene mutations in Korean patients with Cowden syndrome and polyposis syndrome. | Q53667014 | ||
| PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. | Q53850298 | ||
| Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. | Q54357561 | ||
| Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. | Q54583947 | ||
| T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance | Q57185252 | ||
| Loss of heterozygosity in sporadic primary cutaneous melanoma | Q58039432 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines | Q61953713 | ||
| Genetics of melanoma | Q67253323 | ||
| Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia | Q68519985 | ||
| Allelic loss on chromosome 10 in prostate adenocarcinoma | Q71046868 | ||
| Chromosome 10 allelic loss in malignant melanoma | Q71612288 | ||
| Frequency of homozygous deletion at p16/CDKN2 in primary human tumours | Q71721193 | ||
| PTEN and MXI1 allelic loss on chromosome 10q is rare in melanoma in vivo | Q73158104 | ||
| PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma | Q73374555 | ||
| Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies | Q73395862 | ||
| Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer | Q73681771 | ||
| Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies | Q73722520 | ||
| PTEN/MMAC1 in malignant melanoma and its importance for tumor progression | Q73739349 | ||
| Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas | Q73957569 | ||
| Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues | Q74093343 | ||
| Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene | Q74608375 | ||
| Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors | Q77470719 | ||
| Epigenetic silencing of the PTEN gene in melanoma | Q79834343 | ||
| Promoter methylation of the PTEN gene is a common molecular change in breast cancer | Q80403566 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1475-1491 | |
| P577 | publication date | 2011-11-11 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Genetic alterations of PTEN in human melanoma | |
| P478 | volume | 69 |
| Q38860973 | Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma |
| Q91525186 | Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis |
| Q90142120 | Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma |
| Q90638319 | Association Between Parkinson's Disease and Melanoma: Putting the Pieces Together |
| Q37662627 | CTGF is a therapeutic target for metastatic melanoma. |
| Q33757319 | Concurrent BRAF and PTEN mutations in melanoma of unknown origin presenting as a breast mass |
| Q45269149 | Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. |
| Q39210082 | Effect of PTEN antisense oligonucleotide on oesophageal squamous cell carcinoma cell lines |
| Q30234505 | Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate |
| Q36741115 | Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway |
| Q39349974 | Genomic characterisation of acral melanoma cell lines |
| Q34667738 | Genotyping of cutaneous melanoma |
| Q53068627 | High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients. |
| Q30365568 | High intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression. |
| Q35746524 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth |
| Q39329609 | Interaction of molecular alterations with immune response in melanoma. |
| Q36553576 | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. |
| Q35830233 | Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration |
| Q36830323 | Melanoma m (zero): diagnosis and therapy |
| Q92666582 | Mesenchymal stem cells promote human melanocytes proliferation and resistance to apoptosis through PTEN pathway in vitiligo |
| Q97424529 | Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma |
| Q57475860 | Multiplex assessment of protein variant abundance by massively parallel sequencing |
| Q54273990 | Mutational and expressional analyses of PTEN gene in colorectal cancer from Northern India. |
| Q38148747 | Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma |
| Q38943508 | Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma |
| Q89993630 | PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition |
| Q38048884 | PTEN and melanomagenesis |
| Q38859960 | PTEN regulates IGF-1R-mediated therapy resistance in melanoma. |
| Q38907413 | Patient-derived tumor xenograft models for melanoma drug discovery |
| Q38653619 | Prognostic and predictive biomarkers in melanoma: an update |
| Q47134263 | Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma |
| Q35140496 | Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis |
| Q36338825 | Revisiting determinants of prognosis in cutaneous melanoma |
| Q38100279 | Rho-associated coiled-coil kinase (ROCK) signaling and disease |
| Q42507904 | Skin cancer: symptoms, mechanistic pathways and treatment rationale for therapeutic delivery |
| Q39173195 | Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations |
| Q92957648 | Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers |
| Q33578398 | Synthetic lethality: emerging targets and opportunities in melanoma |
| Q38082327 | Targeted therapy for melanoma: rational combinatorial approaches |
| Q33917630 | Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q38998443 | Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. |
| Q91826180 | The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response |
| Q34518472 | The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation |
| Q38219616 | Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). |
| Q35313400 | Voltage-sensing phosphatase modulation by a C2 domain |
| Q39456830 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. |
Search more.